Today: 11 April 2026
Subscribe
Browse Category

NYSE:PFE 23 December 2025 - 1 January 2026

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer stock in focus on New Year’s Day after report of 2026 U.S. drug price hikes

Pfizer shares slipped 0.4% to $24.90 after hours following a report the company will raise U.S. list prices on about 80 medicines in 2026, including a 15% hike for its COVID vaccine Comirnaty. Most Pfizer increases are under 10%. U.S. stock markets were closed Thursday for New Year’s Day. Investors await Pfizer’s Feb. 3 results and 2026 outlook.
1 January 2026
···
Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer stock dips after-hours as 2026 drug price hike list puts PFE in the spotlight

Pfizer shares fell 0.4% to $24.90 in after-hours trading after reports the company will lead U.S. drug list-price increases in 2026, including a 15% hike for its COVID vaccine. Healthcare data show Pfizer plans about 80 price increases, as drugmakers prepare for the annual January price reset under political scrutiny. Investors await further pricing updates and Pfizer’s February earnings call.
1 January 2026
···
Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer stock flat after hours as TD Cowen sticks with Hold; Feb. 3 results ahead

Pfizer shares slipped 0.02% to $24.99 in late after-hours trading Tuesday. TD Cowen reiterated a Hold rating and $30 price target, citing weak longer-term trends. Investors await Pfizer’s next results for signs it can offset declining COVID sales and upcoming patent expirations. Pfizer forecasts 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00.
31 December 2025
···
Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer stock today: PFE edges up after TD Cowen sticks with Hold as investors size up 2026 outlook

Pfizer shares edged up 0.1% to $25.03 Tuesday after TD Cowen reiterated a Hold rating and $30 price target, citing negative trends through 2030. The company projected 2026 revenue of $59.5 billion to $62.5 billion and warned of a “bumpy” period ahead as COVID demand fades and key patents expire. Shares have dropped over 50% since early 2023. Pfizer’s next earnings report is set for February 3.
30 December 2025
··
Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer stock today: PFE edges down as Wall Street looks to Feb. 3 results update

Pfizer shares slipped 0.1% to $25.06 in thin holiday trading Monday, with the stock moving between $24.99 and $25.19. Investors focused on Pfizer’s 2026 outlook and pipeline moves, including a $150 million licensing deal with China’s YaoPharma for an experimental obesity drug. Broader U.S. markets declined as tech stocks retreated. Pfizer expects revenue growth to resume in 2029.
29 December 2025
···
Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer Stock (PFE) Update: Shares Hold Near $25 Into Year-End as Investors Weigh 2026 Guidance, Dividend, and Pipeline Catalysts

Pfizer shares closed Friday at $25.09, trading in a narrow range on light volume ahead of the New Year’s holiday. No new company press releases have appeared since Dec. 18. The stock remains below its 52-week high of $27.69, with dividend yield drawing investor focus as Wall Street weighs declining COVID revenues against future growth in oncology and obesity drugs.
27 December 2025
···
Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer (PFE) Stock News, Forecasts and Analyst Outlook as of Dec. 25, 2025

Pfizer shares closed at $25.03 on Dec. 24, ahead of Christmas, after the company issued 2026 guidance below Wall Street forecasts. The drugmaker projected 2026 revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, citing lower COVID product sales and loss of exclusivity. Pfizer declared a $0.43 per share Q1 2026 dividend, its 349th consecutive payout.
25 December 2025
···
Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer (PFE) Stock News Today: 2026 Guidance, Drug-Price Deals, Pipeline Catalysts, and Analyst Forecasts (Dec. 24, 2025)

Pfizer shares traded near $25 on Dec. 24, 2025, valuing the company at about $142 billion amid thin holiday trading. The company’s 2026 guidance, released Dec. 16, projects revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, with growth not expected to rebound until later in the decade. Investors remain focused on drug pricing risks, pipeline progress, and looming patent expirations.
24 December 2025
···
Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

Pfizer Stock (PFE) on Dec. 24, 2025: Latest News, 2026 Guidance, Dividend, and Analyst Forecasts

Pfizer shares traded near $24.93 in thin holiday trading Dec. 24 after the company reported a patient death in a long-term study of its hemophilia drug Hympavzi. The company said it does not expect the event to alter the drug’s safety profile. U.S. policy moves to lower drug costs also weighed on sentiment. Pfizer reaffirmed 2025 earnings guidance and issued conservative 2026 forecasts.
24 December 2025
·
Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer (PFE) Stock After Hours: What’s Moving Shares After the Dec. 23, 2025 Close—and What to Watch Before Dec. 24’s Open

Pfizer shares closed down 1.31% at $24.88 on December 23 after news that a patient died in a long-term trial of its hemophilia drug Hympavzi. The patient suffered a stroke and brain hemorrhage following minor surgery, according to the European Haemophilia Consortium. Trading volume was lighter than average ahead of the holiday. Pfizer said it is working with investigators and regulators to review the case.
24 December 2025
··
Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer Stock (PFE) Update Dec. 23, 2025: Hympavzi Safety Alert, 2026 Guidance, Dividend, and What Analysts Are Watching

Pfizer shares traded near $25.15 on Dec. 23 after a fatal thrombotic stroke was reported in a patient on its hemophilia therapy Hympavzi, prompting scrutiny from advocacy groups. The company also issued 2026 guidance projecting revenue of $59.5–$62.5 billion and adjusted EPS of $2.80–$3.00, below analyst expectations.
23 December 2025
···
1 2 3 4 5 6 … 10

Stock Market Today

  • Top 5 Singapore Next 50 Stocks Outperform Blue Chips in Q1 2026
    April 11, 2026, 12:17 AM EDT. In Q1 2026, amid market volatility spurred by geopolitical tensions and rising oil prices, five Singapore Next 50 stocks outpaced blue chips with substantial gains. Frencken Group led with a 47.8% total return, driven by confidence in semiconductor recovery and expected capacity expansions in the US, Singapore, and Malaysia. The company reported better-than-expected FY2025 margins and growth in semiconductor and industrial automation divisions, despite a revenue dip in analytical life sciences. These outperformers highlight resilient pockets within Singapore equities, offering investors diversification beyond traditional blue chips during a turbulent first quarter.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 11.04.2026

11 April 2026
LIVEMarkets rolling coverageStarted: April 11, 2026, 12:00 AM EDTUpdated: April 11, 2026, 12:38 AM EDT Top 5 Singapore Next 50 Stocks Outperform Blue Chips in Q1 2026 April 11, 2026, 12:17 AM EDT. In Q1 2026, amid market volatility spurred by geopolitical tensions and rising oil prices, five Singapore Next 50 stocks outpaced blue chips with substantial gains. Frencken Group led with a 47.8% total return, driven by confidence in semiconductor recovery and expected capacity expansions in the US, Singapore, and Malaysia. The company reported better-than-expected FY2025 margins and growth in semiconductor and industrial automation divisions, despite a revenue dip
UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

UK Stock Market Today: FTSE 100 Climbs as Traders Eye Fragile Iran Ceasefire

10 April 2026
London’s FTSE 100 rose 0.38% to 10,644.28 late Friday morning as investors awaited U.S.-Iran talks in Pakistan. Brent crude climbed 1% to $96.83 a barrel, while sterling eased but was on track for its biggest weekly gain since January. The FTSE 250 gained 0.79%. Britain’s 10-year gilt yield stood at 4.807%.
US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

US Stock Market Today: CPI, Oil and Iran Truce Set the Tone Before the Open

10 April 2026
Dow e-minis slipped 0.15% before Friday’s open, with S&P 500 and Nasdaq 100 futures each down 0.08% as traders awaited March CPI data and watched U.S.-Iran tensions. Economists expect headline CPI to rise 0.9% for March and 3.3% year-on-year. Weekly jobless claims increased to 219,000. Brent crude traded near $97 a barrel, while shipping through the Strait of Hormuz remained well below normal.
Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 10.04.2026

10 April 2026
LIVEMarkets rolling coverageStarted: April 10, 2026, 12:00 AM EDTUpdated: April 10, 2026, 11:59 PM EDT Orora ASX:ORA Faces Earnings Reset After Saverglass Impact and Middle East Disruptions April 10, 2026, 11:59 PM EDT. Orora (ASX:ORA) shares plunged over 8% in one day following a guidance update that revealed an earnings reset at its Saverglass unit due to Middle East supply chain disruptions and a shutdown at the Ras Al Khaimah glass plant. Despite a sharp short-term loss, Orora's 90-day share price rise exceeds 33%, contrasting a longer-term 10.58% annual total shareholder return decline amid ongoing sector pressures. Trading at A$1.49,
Go toTop